BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...
Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited ...
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback